Collegium Pharmaceutical
COLL
Halozyme Therapeutics
HALO
Precision Drilling
PDS
Hutchmed (China)
HCM
Enerpac Tool
EPAC
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | 493.17%35.02M | 15,102.63%17.33M | 608.03%11.37M | -118.92%-454K | 279.32%6.77M | 585.44%5.9M | -74.32%114K | -27.40%1.61M | 200.97%2.4M | 219.25%1.78M |
Net income from continuing operations | 3,325.53%28.68M | 522.16%10.3M | 4,440.73%17.39M | 98.90%-9K | 146.85%990K | 92.59%-889K | 184.58%1.66M | 111.52%383K | 78.73%-815K | 26.89%-2.11M |
Operating gains losses | 18.26%1.24M | 13.33%289K | 118.58%553K | -69.82%86K | 22.13%309K | 10.92%1.05M | -30.33%255K | -7.66%253K | -2.40%285K | 2,200.00%253K |
Depreciation and amortization | 22.90%5.8M | 27.49%1.58M | 24.09%1.54M | 23.20%1.42M | 16.04%1.27M | 21.27%4.72M | 17.47%1.24M | 22.23%1.24M | 21.03%1.15M | 24.97%1.09M |
Deferred tax | -1,932.25%-5.61M | 448.72%544K | -28,254.55%-6.19M | 297.92%95K | 42.55%-54K | -227.19%-276K | -524.00%-156K | -70.67%22K | -139.02%-48K | -313.64%-94K |
Change In working capital | 103.62%114K | 162.24%2.7M | -112.02%-2.77M | -476.21%-3.04M | 91.22%3.22M | -269.92%-3.15M | -1,025.45%-4.33M | -138.73%-1.31M | 185.94%807K | 959.69%1.69M |
-Change in receivables | -187.10%-14.69M | -49.41%-5.85M | -96.84%-4.86M | -3,499.17%-4.11M | -88.08%137K | -492.63%-5.12M | -912.40%-3.92M | -274.29%-2.47M | 156.81%121K | 135.93%1.15M |
-Change in prepaid assets | -700.27%-2.23M | -1,212.99%-1.01M | -693.51%-1.47M | -66.39%160K | -45.57%86K | 264.60%372K | -955.56%-77K | -112.64%-185K | 660.00%476K | 350.79%158K |
-Change in payables and accrued expense | 373.18%9.49M | 703.62%5.78M | 31.17%1.52M | 4,781.25%3M | -506.63%-797K | 16,616.67%2.01M | 408.58%719K | -40.06%1.16M | 91.37%-64K | 120.85%196K |
-Change in other current assets | 788.30%1.18M | 600.00%504K | 196.18%277K | -225.00%-30K | 1,928.57%426K | -122.80%-171K | 350.00%72K | -158.66%-288K | -75.76%24K | -85.42%21K |
-Change in other working capital | 2,774.79%6.37M | 390.52%3.28M | 267.71%1.77M | -919.60%-2.05M | 1,993.17%3.37M | -1,930.77%-238K | -637.62%-1.13M | 228.00%480K | 12,400.00%250K | -8.52%161K |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | 493.17%35.02M | 15,102.63%17.33M | 608.03%11.37M | -118.92%-454K | 279.32%6.77M | 585.44%5.9M | -74.32%114K | -27.40%1.61M | 200.97%2.4M | 219.25%1.78M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | -52.65%-7.74M | -78.23%-2.22M | -11.32%-1.46M | -235.96%-2.73M | 21.56%-1.34M | 27.90%-5.07M | 30.06%-1.25M | 19.07%-1.31M | 52.21%-812K | 11.96%-1.71M |
Capital expenditure reported | -39.13%-7.74M | -78.38%-2.22M | -11.24%-1.46M | -108.24%-2.73M | 21.33%-1.34M | 14.74%-5.56M | 2.28%-1.24M | 19.01%-1.31M | 22.90%-1.31M | 12.22%-1.7M |
Net investment purchase and sale | --0 | --0 | --0 | --0 | --0 | 197.24%493K | 99.80%-1K | --1K | --498K | ---5K |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | -52.65%-7.74M | -78.23%-2.22M | -11.32%-1.46M | -235.96%-2.73M | 21.56%-1.34M | 27.90%-5.07M | 30.06%-1.25M | 19.07%-1.31M | 52.21%-812K | 11.96%-1.71M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | 110.93%6.06M | 13,530.23%5.86M | -123.16%-195K | -60.66%683K | -215.94%-291K | 1,035.50%2.87M | 158.90%43K | 1,236.51%842K | 709.12%1.74M | 2,191.67%251K |
Net issuance payments of debt | ---- | ---- | ---- | 97.54%-3K | -315.71%-291K | ---- | ---- | ---- | ---122K | ---70K |
Proceeds from stock option exercised by employees | 100.60%6.67M | 3,428.92%5.86M | -97.24%27K | -57.86%783K | --0 | 901.20%3.32M | 196.43%166K | 919.79%979K | 1,106.49%1.86M | 1,134.62%321K |
Net other financing activities | -34.96%-610K | 102.44%3K | ---516K | ---- | ---- | ---452K | ---123K | ---- | ---- | ---- |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | 110.93%6.06M | 13,530.23%5.86M | -123.16%-195K | -60.66%683K | -215.94%-291K | 1,035.50%2.87M | 158.90%43K | 1,236.51%842K | 709.12%1.74M | 2,191.67%251K |
Net cash flow | ||||||||||
Beginning cash position | 40.99%13.81M | 77.99%26.36M | 20.93%16.51M | 83.69%18.98M | 40.99%13.81M | -48.20%9.79M | 38.06%14.81M | 30.25%13.65M | -33.04%10.33M | -48.20%9.79M |
Current changes in cash | 799.89%33.33M | 2,027.67%20.97M | 751.97%9.72M | -175.20%-2.5M | 1,466.16%5.14M | 143.29%3.7M | 22.78%-1.09M | 72.88%1.14M | 176.22%3.32M | 109.52%328K |
Effect of exchange rate changes | -182.26%-255K | -653.66%-454K | 605.26%134K | 3,400.00%33K | -84.76%32K | 155.96%310K | -82.63%82K | 104.61%19K | 99.83%-1K | 850.00%210K |
End cash Position | 239.58%46.88M | 239.58%46.88M | 77.99%26.36M | 20.93%16.51M | 83.69%18.98M | 40.99%13.81M | 40.99%13.81M | 38.06%14.81M | 30.25%13.65M | -33.04%10.33M |
Free cash flow | 7,945.43%27.27M | 1,437.35%15.11M | 3,227.52%9.92M | -392.19%-3.18M | 6,519.51%5.43M | 104.38%339K | -36.31%-1.13M | -50.08%298K | 126.72%1.09M | 102.39%82K |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |